AOD-9604
Burns fat without growth hormone effects
- Fat Loss
- Weight Loss Stalls
Phase 2 osteoarthritis trial completed; the program did not advance to Phase 3 — no completed Phase 3 OA trial exists Never received regulatory approval for any indication Listed on WADA prohibited substances list — banned in competitive sports Limited published human safety data despite Phase 2/3 trial history Black market products may contain contaminants or incorrect dosing
Mechanism of Action
AOD-9604 is a modified hGH C-terminal fragment (amino acids 176–191) with an N-terminal tyrosine addition, designed to retain the lipolytic (fat-burning) properties of hGH without its growth-promoting or diabetogenic effects. It appears to enhance lipolysis and increase energy expenditure through mechanisms that involve but do not solely depend on beta-3 adrenergic receptor activation, suggesting alternative or redundant pathways in fat metabolism. Key Pathways: Beta-3 adrenergic receptor signaling, Lipolysis and fat oxidation pathways, Energy expenditure regulation In obese animal models, AOD-9604 reduced body weight and fat mass while increasing fat oxidation and energy expenditure. These effects suggest potential utility for fat loss, though the translation of these findings to humans remains incompletely established despite early-phase clinical trials.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full AOD-9604 protocols — frequency, timing, cycle length, reconstitution & research
- Injection site reactions
- Headache
- Nausea